You are here

Article Text

Article menu
Download PDFPDF
Letters
Anti-titin antibodies are not associated with a specific thymoma histology
  1. R Voltz1,2,
  2. W Albrich1,
  3. R Hohlfeld1,2,
  4. D Nagel3,
  5. M Wick3,
  6. T Kirchner4,
  7. N Sommer5,
  8. I Illa6,
  9. H Kaminski7,
  10. F Schumm8
  1. 1Institute of Clinical Neuroimmunology, Klinikum Gosshadern, München, Germany
  2. 2Department of Neurology, Klinikum Gosshadern, München
  3. 3Department of Clincial Chemistry, Klinikum Gosshadern, München
  4. 4Department of Pathology, University of Erlangen, Germany
  5. 5Department of Neurology, University of Marburg, Germany
  6. 6Servei Neurologia, Hospital Sant Pau, Universitat Autònoma Barcelona, Spain
  7. 7Department of Neurology, Case Western Reserve University, Cleveland, USA
  8. 8Department of Neurology, Christophsbad, Göppingen, Germany
  1. Correspondence to:
    Dr R Voltz;
    rvoltz{at}nro.med.uni-meunchen.de

https://doi.org/10.1136/jnnp.74.2.282

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    After the first description of antibodies to titin in patients with thymoma associated myasthenia gravis in 1990, this finding was independently confirmed and the main immunogenic region of titin (mgt30) identified.1 This 30 kDa part of titin is now also commercially available as antigen for detecting anti-titin antibodies. Furthermore, in a series of 276 patients, we could confirm the clinical usefulness of measuring anti-titin antibodies for predicting the presence of a thymic epithelial tumour in patients with myasthenia gravis that was significantly better than the …

    View Full Text

    Footnotes

    • Competing interests: none declared.